View in EDS

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Saved in:
Bibliographic Details
Title: The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.
Authors: Gill H; Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China., Yacoub A; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Cancer Center, Kansas City, KS., Gerds AT; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Shortt J; Department of Medicine, School of Clinical Sciences, Monash University and Monash Haematology, Monash Health, Clayton, VIC, Australia., Rossetti JM; Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA., Mead AJ; Medical Research Council Weatherall Institute of Molecular Medicine and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Göthert JR; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany., Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen, Germany., Ewing J; Haematology Department, University of Birmingham, Birmingham, United Kingdom., Halpern AB; Division of Hematology and Oncology, University of Washington Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Palandri F; Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy., Passamonti F; Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Mesa R; Medical Oncology and Hematology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC., Marchetti M; Hematology and Transplant Unit, Azienda Ospedaliera Universitaria, Alessandria, Italy., Harrison C; Department of Clinical Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom., Vannucchi AM; Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, Florence, Italy., Watts JM; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, FL., Wood JC; Department of Pediatrics and Radiology, Children's Hospital Los Angeles, Los Angeles, CA., Ross DM; Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia., Peppe J; Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ., Natsoulis G; Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ., Rienhoff HY Jr; Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ.
Source: Blood advances [Blood Adv] 2026 Jul 14; Vol. 10 (13), pp. 4585-4594.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42054549
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gill+H%22">Gill H</searchLink>; Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.<br /><searchLink fieldCode="AU" term="%22Yacoub+A%22">Yacoub A</searchLink>; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Cancer Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Gerds+AT%22">Gerds AT</searchLink>; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.<br /><searchLink fieldCode="AU" term="%22Shortt+J%22">Shortt J</searchLink>; Department of Medicine, School of Clinical Sciences, Monash University and Monash Haematology, Monash Health, Clayton, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Rossetti+JM%22">Rossetti JM</searchLink>; Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA.<br /><searchLink fieldCode="AU" term="%22Mead+AJ%22">Mead AJ</searchLink>; Medical Research Council Weatherall Institute of Molecular Medicine and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Göthert+JR%22">Göthert JR</searchLink>; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Koschmieder+S%22">Koschmieder S</searchLink>; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen, Germany.<br /><searchLink fieldCode="AU" term="%22Ewing+J%22">Ewing J</searchLink>; Haematology Department, University of Birmingham, Birmingham, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Halpern+AB%22">Halpern AB</searchLink>; Division of Hematology and Oncology, University of Washington Medicine, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Palandri+F%22">Palandri F</searchLink>; Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Passamonti+F%22">Passamonti F</searchLink>; Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Mesa+R%22">Mesa R</searchLink>; Medical Oncology and Hematology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC.<br /><searchLink fieldCode="AU" term="%22Marchetti+M%22">Marchetti M</searchLink>; Hematology and Transplant Unit, Azienda Ospedaliera Universitaria, Alessandria, Italy.<br /><searchLink fieldCode="AU" term="%22Harrison+C%22">Harrison C</searchLink>; Department of Clinical Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Vannucchi+AM%22">Vannucchi AM</searchLink>; Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22Watts+JM%22">Watts JM</searchLink>; Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Leonard M. Miller School of Medicine, Miami, FL.<br /><searchLink fieldCode="AU" term="%22Wood+JC%22">Wood JC</searchLink>; Department of Pediatrics and Radiology, Children's Hospital Los Angeles, Los Angeles, CA.<br /><searchLink fieldCode="AU" term="%22Ross+DM%22">Ross DM</searchLink>; Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia.<br /><searchLink fieldCode="AU" term="%22Peppe+J%22">Peppe J</searchLink>; Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ.<br /><searchLink fieldCode="AU" term="%22Natsoulis+G%22">Natsoulis G</searchLink>; Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ.<br /><searchLink fieldCode="AU" term="%22Rienhoff+HY+Jr%22">Rienhoff HY Jr</searchLink>; Imago BioSciences Inc, a subsidiary of Merck & Co, Inc, Rahway, NJ.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2026 Jul 14; Vol. 10 (13), pp. 4585-4594.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42054549
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2025018141
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4585
    Titles:
      – TitleFull: The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gill H
      – PersonEntity:
          Name:
            NameFull: Yacoub A
      – PersonEntity:
          Name:
            NameFull: Gerds AT
      – PersonEntity:
          Name:
            NameFull: Shortt J
      – PersonEntity:
          Name:
            NameFull: Rossetti JM
      – PersonEntity:
          Name:
            NameFull: Mead AJ
      – PersonEntity:
          Name:
            NameFull: Göthert JR
      – PersonEntity:
          Name:
            NameFull: Koschmieder S
      – PersonEntity:
          Name:
            NameFull: Ewing J
      – PersonEntity:
          Name:
            NameFull: Halpern AB
      – PersonEntity:
          Name:
            NameFull: Palandri F
      – PersonEntity:
          Name:
            NameFull: Passamonti F
      – PersonEntity:
          Name:
            NameFull: Mesa R
      – PersonEntity:
          Name:
            NameFull: Marchetti M
      – PersonEntity:
          Name:
            NameFull: Harrison C
      – PersonEntity:
          Name:
            NameFull: Vannucchi AM
      – PersonEntity:
          Name:
            NameFull: Watts JM
      – PersonEntity:
          Name:
            NameFull: Wood JC
      – PersonEntity:
          Name:
            NameFull: Ross DM
      – PersonEntity:
          Name:
            NameFull: Peppe J
      – PersonEntity:
          Name:
            NameFull: Natsoulis G
      – PersonEntity:
          Name:
            NameFull: Rienhoff HY Jr
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 14
              M: 07
              Text: 2026 Jul 14
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 13
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1